Sedana Medical AB

As of June 30, 2026, Sedana Medical AB carries a market capitalization of 822.51M, placing it among publicly traded companies globally. Its enterprise value stands at 778.04M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Sedana Medical AB's next confirmed earnings release is scheduled for October 22, 2026.

As of June 30, 2026, Sedana Medical AB has 99.34M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 4.03, and the price-to-book ratio stands at 0.93.

These figures are as of June 30, 2026. The EV/Sales ratio of 3.81 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 778.04M versus a market cap of 822.51M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Sedana Medical AB maintains a current ratio of 2.89, meaning it holds 2.9x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Sedana Medical AB posted a negative return on equity (ROE) of -4.03, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -3.80, reflecting losses generated across the asset base. The company generates approximately 1.72M in revenue per employee across its workforce of 118.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.39 indicates how many times Sedana Medical AB sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Sedana Medical AB recorded 3.13M in income tax expense. The company reported a pretax loss of -33.58M and -36.71M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Sedana Medical AB's stock has declined approximately 24.68% over the past 52 weeks. The 50-day moving average sits at 10.45, while the 200-day moving average is 9.66.

Over the twelve months ended June 30, 2026, Sedana Medical AB generated 204.01M in revenue and converted that into -36.71M in net income, yielding earnings per share of -0.37. EBITDA reached -4.09M, while operating income came in at -30.60M.

As of June 30, 2026, Sedana Medical AB holds 51.79M in cash and equivalents against 7.32M in total debt, resulting in a net debt position of -51.79M. Total book value stands at 888.45M, with working capital of 85.55M providing operational flexibility.

Sedana Medical AB produced -22.70M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -64.52M in capital expenditures, free cash flow totaled -87.22M - equivalent to -0.88 per share.

Over the twelve months ended June 30, 2026, Sedana Medical AB posted a gross margin of 71.63, reflecting its pricing power and cost economics. The operating margin of -15.00 and net profit margin of -17.99 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -10.60: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 0.55, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Sedana Medical AB shareholders.

Sedana Medical AB's most recent stock split took place on May 26, 2021 with a 1:4 split ratio.

As of June 30, 2026, Sedana Medical AB has an Altman Z-Score of 8.18, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.